Dexcom, which develops, manufactures and distributes continuous glucose monitoring (CMS) systems for diabetes management, has released the G5 Mobile CGM System, the only FDA-approved system that lets people with type 1 or type 2 diabetes make treatment decisions without pricking a finger.
For the 1.25 million Americans living with type 1 diabetes (out of 29.1 million diabetics in the US), this replaces the need to painfully prick fingers multiple times throughout the day to measure blood glucose levels and give themselves insulin injections.
The Dexcom G5 CGM System provides real-time glucose readings every five minutes, anywhere, anytime, to a smart device and is safe for adults and pediatric patients two years of age and older. It also sends high/low glucose alerts and alarms, and allows users to share their glucose data with up to five followers.
DexCom currently holds more than 40 patents and the company’s roots stem from 1967 research on implanted glucose sensors based on creating an implantable sensor the body would not reject and that would perform for a long period of time.
“At Dexcom, our mission is to empower people to take control of their diabetes. Managing blood sugars is a 24/7 job and is full of so many inconveniences,” Dexcom CEO & President, Kevin Sayer told brandchannel. “As a result, the majority of people with diabetes struggle to keep their blood sugar levels in a safe range. And failing to keep your sugars in range can result in long-term and short term health complications.”
The Dexcom G5 CGM System, added Sayer, “is designed to address the needs our customers, and tell them the information that is most critical to them, so they can do a better job managing their glucose levels.”
Sayer explained that Dexcom has data to prove its usage improves outcomes. “A recently released clinical study by the Journal of the American Medical Association shows that CGM users experienced an average 1% reduction of their A1C (blood glucose levels) after 24 weeks of regular use and experienced significant reductions in the time spent in hyperglycemia (high blood glucose) and hypoglycemia (low blood glucose).”
Dexcom videos for G5 CGM feature agency planner Stefanie Riediger, who was diagnosed at 22 months with type 1 diabetes. As the campaign began, Riediger’s mother brought in dozens of the small books she used to document every time she pricked her daughter’s tiny fingers, thousands of pricks each year. Every day, she recorded left, center, right of each finger so she could make sure she wasn’t pricking in the same place too often.
It was the notebooks that sparked the idea to celebrate the fingers of those looking for a brighter future. Every person in the Dexcom videos, from the 2-year-old to the 80-year-old whose hands are seen helping a small child learn to ride a bike, has type 1 diabetes.
brandchannel spoke with Jen Loving, who has two daughters with type 1 diabetes, about how Dexcom has changed their lives.
“Dexcom gives my girls anonymity,” said Loving. “They can be ‘normal’ kids without me nagging to them about checking their blood sugars. I just look at my Share app and can see what their blood sugars are at any time.”
Overnights are now easier, added Loving. “When the girls spend the night away from home, I don’t have to worry about them texting me before bed to tell me what their blood sugar is. I am alerted if they are not in range, and can contact them, or the person they are staying with to make sure they take action.”
— Heath Care News (@hc_equipment) February 15, 2017
And finally, she added, she has “peace of mind for my girls. Diabetes care causes a lot of anxiety. Having an accurate readout with Dexcom helps the girls be confident in whatever activity they are involved with at the moment.”
Continuing to innovate, Dexcom plans to make the technology smaller, more discreet and more digitally connected. “As a result of Dexcom’s partnership with Google’s Verily, we are also working to integrate more analytics based on data that includes lifestyle information,” noted Sayer. “In addition, Dexcom is the CGM used in 90% of the artificial pancreas studies currently being conducted.”